TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stroke With Transfusions Changing to Hydroxyurea
Brief Summary: The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia (SCA).


Options:
A: Intervention Type: PROCEDURE; Name: Blood Transfusion; Assigned to Arm(s): N/A
B: Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group
C: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stroke With Transfusions Changing to Hydroxyurea
Brief Summary: The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia (SCA).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1
B: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm
C: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid
D: Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Physician Partnership to Improve High Blood Pressure Adherence
Brief Summary: To test the efficacy of a patient-centered, culturally tailored education and activation intervention designed to improve adherence to medication and life style recommendations among adults with uncontrolled hypertension.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A
C: Arm Label: Use of a Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient navigation | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Patient navigation; Assigned to Arm(s): Use of a Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
D: Intervention Type: BEHAVIORAL; Name: health education; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Take Control of Your Blood Pressure (TCYB)
Brief Summary: The purpose of this study is to improve adherence to blood pressure (BP) monitoring and medication compliance in individuals with high BP.


Options:
A: Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor
B: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: GMV Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GMV Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention | Intervention Type: BEHAVIORAL; Name: GMV Intervention; Assigned to Arm(s): GMV Intervention
D: Arm Label: Telemedicine; Type: OTHER; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedicine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Health and Ventilator-associated Pneumonia
Brief Summary: Recent studies have found that poor oral hygiene may foster the colonization of the oropharynx by potential respiratory pathogens in mechanically-ventilated (MV), intensive care unit (ICU) patients. Thus, improvements in oral hygiene in MV-ICU patients may prevent ventilator-associated pneumonia (VAP).

The specific aims of this investigation are: 1) to organize the necessary infrastructure to develop and perform a pilot clinical trial to evaluate alternative oral hygiene procedures to prevent VAP; 2) to use this organization to perform a pilot clinical trial to determine if the use of oral topical chlorhexidine gluconate (CHX) will prevent dental plaque, oropharyngeal colonization by respiratory pathogens, and VAP in MV-ICU patients.


Options:
A: Intervention Type: DRUG; Name: Chlorhexidine gluconate (drug) vs placebo; Assigned to Arm(s): N/A
B: Arm Label: Placebo (Vehicle Control); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 0.12% chlorhexidine gluconate oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%) | Arm Label: 0.12% chlorhexidine oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%), Drug: placebo | Intervention Type: DRUG; Name: chlorhexidine gluconate oral rinse (0.12%); Assigned to Arm(s): 0.12% chlorhexidine gluconate oral rinse, 0.12% chlorhexidine oral rinse | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 0.12% chlorhexidine oral rinse, Placebo (Vehicle Control)
C: Arm Label: Oral Chlorhexidine Mouth Rinse; Type: OTHER; Interventions: Other: Chlorhexidine Mouth Rinse | Arm Label: De-Adoption of Oral Chlorhexidine Mouth Rinse; Type: EXPERIMENTAL; Interventions: Other: Chlorhexidine Mouth Rinse De-Adoption | Intervention Type: OTHER; Name: Chlorhexidine Mouth Rinse; Assigned to Arm(s): Oral Chlorhexidine Mouth Rinse | Intervention Type: OTHER; Name: Chlorhexidine Mouth Rinse De-Adoption; Assigned to Arm(s): De-Adoption of Oral Chlorhexidine Mouth Rinse
D: Arm Label: 0.12% Chlorhexidie Digluconate; Type: EXPERIMENTAL; Interventions: Drug: 0.12% Chlorhexidine Digluconate | Arm Label: Toothbrushing; Type: PLACEBO_COMPARATOR; Interventions: Other: Toothbrushing | Intervention Type: DRUG; Name: 0.12% Chlorhexidine Digluconate; Assigned to Arm(s): 0.12% Chlorhexidie Digluconate | Intervention Type: OTHER; Name: Toothbrushing; Assigned to Arm(s): Toothbrushing

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Health and Ventilator-associated Pneumonia
Brief Summary: Recent studies have found that poor oral hygiene may foster the colonization of the oropharynx by potential respiratory pathogens in mechanically-ventilated (MV), intensive care unit (ICU) patients. Thus, improvements in oral hygiene in MV-ICU patients may prevent ventilator-associated pneumonia (VAP).

The specific aims of this investigation are: 1) to organize the necessary infrastructure to develop and perform a pilot clinical trial to evaluate alternative oral hygiene procedures to prevent VAP; 2) to use this organization to perform a pilot clinical trial to determine if the use of oral topical chlorhexidine gluconate (CHX) will prevent dental plaque, oropharyngeal colonization by respiratory pathogens, and VAP in MV-ICU patients.


Options:
A: Arm Label: Toothbrushing with a manual brush; Type: EXPERIMENTAL; Interventions: Device: Toothbrushing with a manual brush | Arm Label: No toothbrushing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Toothbrushing with a manual brush; Assigned to Arm(s): Toothbrushing with a manual brush
B: Arm Label: Placebo (Vehicle Control); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 0.12% chlorhexidine gluconate oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%) | Arm Label: 0.12% chlorhexidine oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%), Drug: placebo | Intervention Type: DRUG; Name: chlorhexidine gluconate oral rinse (0.12%); Assigned to Arm(s): 0.12% chlorhexidine gluconate oral rinse, 0.12% chlorhexidine oral rinse | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 0.12% chlorhexidine oral rinse, Placebo (Vehicle Control)
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: oral hygiene | Intervention Type: OTHER; Name: oral hygiene; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Oral Care | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Comprehensive Oral Care | Intervention Type: PROCEDURE; Name: Standard Oral Care; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Comprehensive Oral Care; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
Brief Summary: The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of methamphetamine dependence.


Options:
A: Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg
D: Arm Label: Smoking-cessation treatment + substance treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Smoking-cessation treatment | Arm Label: Substance-treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smoking-cessation treatment; Assigned to Arm(s): Smoking-cessation treatment + substance treatment as usual

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Brief Summary: The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of cocaine dependence.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
B: Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): N/A
C: Arm Label: Smoking-cessation treatment + substance treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Smoking-cessation treatment | Arm Label: Substance-treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smoking-cessation treatment; Assigned to Arm(s): Smoking-cessation treatment + substance treatment as usual
D: Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Brief Summary: Eosinophilic esophagitis (EE) is an increasingly recognized condition characterized by dysphagia, food impaction or other obstructive esophageal symptoms in children and young adults.

The pathophysiology of EE appears to be an allergy/atopy mediated disease. A personal and family history of allergic diseases (food allergies, atopic dermatitis, asthma, allergic rhinitis or conjunctivitis) has been noted in 62-85% of patients with EE. The rising incidence of EE may be related to the worldwide allergy and asthma epidemic.

Current treatment of EE is directed at decreasing esophageal allergic inflammation. Oral and topical corticosteroids, cromolyn sodium, montelukast and elemental/elimination diets have all been shown to be effective. However, none of these treatments are directed at the specific pathophysiologic mechanism of EE and some have significant side effects.

The shared pathogenetic mechanisms of EE and asthma suggest that therapeutic strategies directed at asthma may also be effective for EE. Specifically those targeted at the allergic immune mechanisms involved with asthma may be effective. Omalizumab is a recently developed anti-IgE antibody that has been shown to decrease the use of inhaled and oral corticosteroids, reduce the frequency of asthma exacerbations, and improve asthma related symptoms in patients with allergic asthma. The objective of the study is to determine the efficacy of omalizumab in the treatment of eosinophilic esophagitis


Options:
A: Arm Label: RPC4046 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: RPC4046 High Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RPC4046; Assigned to Arm(s): RPC4046 High Dose, RPC4046 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide plus Prevacid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo plus Prevacid | Intervention Type: DRUG; Name: Budesonide plus Prevacid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo plus Prevacid; Assigned to Arm(s): 2
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Oral cromolyn; Type: EXPERIMENTAL; Interventions: Drug: oral cromolyn sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral cromolyn sodium; Assigned to Arm(s): Oral cromolyn | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis
Brief Summary: Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be related to both allergies and acid reflux. There have been reports that both swallowed, aerosolized steroids and proton pump inhibitors have been effective treatments. The researchers propose to directly compare the efficacy of aerosolized fluticasone to esomeprazole in the treatment of eosinophilic esophagitis. The hypothesis is that aerosolized fluticasone (Flovent) will be more effective in relieving symptoms of EE than esomeprazole (Nexium) treatment. Patients will undergo endoscopy, pH monitoring and manometry for diagnosis. Following diagnosis of EE by pathology (biopsy of esophagus), patients will be randomized to esomeprazole or swallowed fluticasone for 8 weeks. At the end of 8 weeks, subjects will be asked to repeat upper endoscopy with biopsies. Three questionnaires (dysphagia, gastroesophageal reflux disease \[GERD\], and allergy) will be completed by the patient at the first endoscopy and at the end endoscopy. The primary objective is to measure change in eosinophil infiltration of the esophagus in response to treatment of allergy (swallowed fluticasone) versus treatment for reflux (esomeprazole) in EE patients.


Options:
A: Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: APT-1011 1.5 mg HS; Type: EXPERIMENTAL; Interventions: Drug: APT-1011, Drug: Placebo | Arm Label: APT-1011 1.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: APT-1011 | Arm Label: APT-1011 3 mg HS; Type: EXPERIMENTAL; Interventions: Drug: APT-1011, Drug: Placebo | Arm Label: APT-1011 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: APT-1011 | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APT-1011; Assigned to Arm(s): APT-1011 1.5 mg BID, APT-1011 1.5 mg HS, APT-1011 3 mg BID, APT-1011 3 mg HS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): APT-1011 1.5 mg HS, APT-1011 3 mg HS, Placebo BID
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone Care Coordination to Improve Smoking Cessation Counseling
Brief Summary: TeleQuit is a group randomized trial testing whether a telephone care coordination program increases the rate of smoking cessation treatment for VA patients at study sites. We are testing whether proactive care coordination (counselor initiates the call to the patient) is more effective than reactive coordination (coordinator waits for the patient to call); and whether multi-session counseling is more effective than brief primary care-based counseling plus self-help materials. We randomly assigned study sites to either quitline counseling or brief counseling only. All patients receive brief smoking cessation counseling from their primary care physician, smoking cessation medications (once they are in contact with the VA care coordinator), and a follow-up call at 6 months. Care coordination will be provided by VA clinical staff. Intensive counseling is provided by the California Smokers' Helpline.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard brief advice | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline intervention | Intervention Type: BEHAVIORAL; Name: Standard brief advice; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Quitline intervention; Assigned to Arm(s): 2
B: Arm Label: Arm 1 - proactive, intensive counseling; Type: EXPERIMENTAL; Interventions: Procedure: Proactive outreach to counseling, Procedure: Intensive counseling | Arm Label: Arm 2 - reactive, intensive counseling; Type: EXPERIMENTAL; Interventions: Procedure: Reactive outreach to counseling, Procedure: Intensive counseling | Arm Label: Arm 3 - proactive, self-help; Type: EXPERIMENTAL; Interventions: Procedure: Proactive outreach to counseling, Procedure: Self-help | Arm Label: Arm 4 - reactive, self-help; Type: EXPERIMENTAL; Interventions: Procedure: Reactive outreach to counseling, Procedure: Self-help | Intervention Type: PROCEDURE; Name: Proactive outreach to counseling; Assigned to Arm(s): Arm 1 - proactive, intensive counseling, Arm 3 - proactive, self-help | Intervention Type: PROCEDURE; Name: Reactive outreach to counseling; Assigned to Arm(s): Arm 2 - reactive, intensive counseling, Arm 4 - reactive, self-help | Intervention Type: PROCEDURE; Name: Intensive counseling; Assigned to Arm(s): Arm 1 - proactive, intensive counseling, Arm 2 - reactive, intensive counseling | Intervention Type: PROCEDURE; Name: Self-help; Assigned to Arm(s): Arm 3 - proactive, self-help, Arm 4 - reactive, self-help
C: Arm Label: Integrated Cessation Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Treatment | Intervention Type: BEHAVIORAL; Name: Tobacco Treatment; Assigned to Arm(s): Integrated Cessation Counseling, Usual Care
D: Intervention Type: BEHAVIORAL; Name: Self-Help Intervention Program-High Blood Pressure; Assigned to Arm(s): N/A

Answer: B